Company Overview and News
We have been long Hormel Foods Corporation (HRL) for a few months now and are up just under $1 a share on our position. I wrote an article about this stock in late February and discussed the strong dividend growth profile of this company. Yes the company has been struggling with top line growth of late but nothing can be taken away from Hormel's balance sheet. It remains one of the best I've researched.
The Procter & Gamble Company (PG - Free Report) or P&G’s board of directors declared a 4% hike in its quarterly cash dividend to 71.72 cents per share, in a bid to impress investors. The dividend will be paid on or after May 15, 2018 to shareholders of record as of Apr 20, 2018. The new figure will add up to an annual dividend of $2.8688 per share. This consumer goods giant has consistently increased its dividend and has been paying dividends for 128 years, ever since its incorporation in 1890.
The U.S. equity market is in jitters as possibilities of a trade war with China and three or more rate hikes by the Federal Reserve do the rounds. When the market is turbulent, the consumer staples sector can be one of the safest go-to places for investors. Predominant as an abode of defensive stocks, this space primarily includes companies that offer products and essentials used in daily lives. However, China’s aggressive stance of slapping 25% tariffs over American imports on Apr 1 has affected the U.
This month’s article marks the thirty-seventh installment in my on-going series outlining my efforts to achieve dividend growth success. The portfolio is nicknamed the MnM portfolio, which is a moniker for “Minne(sota) ‘n Monthly.”
Hormel Foods (HRL) has established a road map to boost its financial performance in a challenging food and beverage environment. The food and beverage space is being negatively impacted by inflation in commodity prices, a consumer preference shift to organic and healthy foods, and the rise of private label products.
Hormel Foods (HRL), one of the leading names in the meat production and packaged foods industry, has seen its stock price fall 4% on a YTD (year-to-date) basis as of April 6, 2018.
Chicago, IL – April 9, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Archer Daniels Midland Company (ADM - Free Report) , Tyson Foods, Inc. (TSN - Free Report) , Hormel Foods Corporation (HRL - Free Report) , Campbell Soup Company (CPB - Free Report) and Brown-Forman Corporation (BF.
The tariff dispute, which has been playing spoilsport, has intensified with President Donald Trump’s latest rhetoric on a potential trade war with China. Trump is seeking a further tariff of $100 billion against China in addition to the already proposed $50 billion of tariffs on Chinese goods, targeting robotics, information technology, communication technology and aerospace. Earlier this week, Washington planned to slap a 25% tariff on 1,300 China-made products, which include a wide array of products including raw materials, construction machinery, agricultural equipment, electronics, medical devices and consumer goods.
Ian's Million Fund "IMF" is a real-money portfolio that I've written about monthly since January 2016 here at Seeking Alpha. The portfolio is a largely buy-and-hold group of ~100 stocks. Each month, I buy 10-25 of the most compelling stocks available at then-current prices, deploying $1,000 of my capital plus accumulated dividends. If things go according to plan, this portfolio, began when I was 27, will hit one million dollars in equity in 2041 at age 52.
2018-04-18 - Asif
History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...
2018-04-16 - Asif
Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...
2018-04-16 - Asif
Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...
2018-04-15 - Asif
Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...
2018-04-12 - Asif
Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...
as of ET